Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exemestane - Pfizer

Drug Profile

Exemestane - Pfizer

Alternative Names: Aromasil; Aromasin; Aromasine; FCE 24304; Nikidess; PNU 155971

Latest Information Update: 22 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Emory University; German Breast Group; Pfizer
  • Class Androstadienes; Antineoplastics; Small molecules
  • Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Jun 2018 German Breast Group and Pfizer completes a phase III trial in Breast cancer (Male breast cancer, Combination therapy, Adjuvant therapy, Neoadjuvant therapy) in Germany (PO) (NCT01638247) (EudraCT2009-015122-11)
  • 22 Jan 2018 Pfizer completes a phase III trial in Breast cancer (Prevention) in USA, Canada, Puerto Rico and France (PO) (NCT00083174)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top